| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21cbff64022f95c237c0bd3ec8656ca |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24151
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24121
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24122 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate |
2018-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_079a238ca0a8942249fa80630ce2f389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba99f5539d99d23315cf4db96d94b289
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca344ea9b69ea563d0841fd6c9a1f7ec |
| publicationDate |
2019-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10240130-B2 |
| titleOfInvention |
CDNA clone-launched platform for high-yield production of inactivated zika virus |
| abstract |
The invention generally relates to the development of variant Zika strains, cDNA clones and mRNA transcripts that contain specific mutations in the Zika ORF, and methods for producing high yields of Zika viruses (“ZIKVs”) using these variant cDNA clones, transcripts and strains. The produced ZIKVs can be used for the manufacture of purified inactivated vaccines (PIVs), which may be useful for treating ZIKV-related diseases and for providing immunoprotection against ZIKV. |
| priorityDate |
2017-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |